“This opens the door to the courts’ second-guessing any FDA approval — especially for drugs for controversial areas like gender-affirming care,” expert says.
View original article
Contributor: David Ovalle
“This opens the door to the courts’ second-guessing any FDA approval — especially for drugs for controversial areas like gender-affirming care,” expert says.
View original article
Contributor: David Ovalle